Key Points
- Mischa Reis sold 9,675 shares of Envista at an average price of $30 (about $290,250), reducing her stake by roughly 23% to 32,382 shares, according to an SEC filing.
- Quarterly results beat expectations: Envista reported $0.38 EPS vs $0.32 expected and $750.6M revenue (up 15% YoY vs $680.3M estimate), and set FY2026 guidance of $1.35–$1.45 EPS.
- Analyst and market momentum is improving—Barclays raised its target to $34 and moved to "overweight," short interest fell ~23% to ~8.09M shares, and the MarketBeat consensus is a Moderate Buy with an average target of $27.43.
Envista Holdings Corporation (NYSE:NVST - Get Free Report) SVP Mischa Reis sold 9,675 shares of the firm's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total value of $290,250.00. Following the transaction, the senior vice president directly owned 32,382 shares of the company's stock, valued at $971,460. This represents a 23.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Envista Price Performance
Shares of Envista stock opened at $30.19 on Thursday. Envista Holdings Corporation has a 52 week low of $14.22 and a 52 week high of $30.42. The company has a current ratio of 2.38, a quick ratio of 2.04 and a debt-to-equity ratio of 0.47. The stock has a market cap of $4.96 billion, a PE ratio of 107.82, a price-to-earnings-growth ratio of 2.06 and a beta of 1.01. The company's 50-day moving average price is $23.36 and its two-hundred day moving average price is $21.43.
Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.06. The company had revenue of $750.60 million for the quarter, compared to analysts' expectations of $680.26 million. Envista had a net margin of 1.73% and a return on equity of 6.54%. The business's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, sell-side analysts anticipate that Envista Holdings Corporation will post 1 EPS for the current fiscal year.
Institutional Investors Weigh In On Envista
Large investors have recently made changes to their positions in the company. Deutsche Bank AG increased its stake in shares of Envista by 2.9% during the 4th quarter. Deutsche Bank AG now owns 17,412 shares of the company's stock worth $378,000 after purchasing an additional 484 shares during the last quarter. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Envista in the 4th quarter valued at $338,000. Fox Run Management L.L.C. boosted its holdings in Envista by 1.8% in the fourth quarter. Fox Run Management L.L.C. now owns 43,982 shares of the company's stock worth $955,000 after purchasing an additional 767 shares in the last quarter. Cerity Partners LLC increased its position in Envista by 257.8% during the fourth quarter. Cerity Partners LLC now owns 47,023 shares of the company's stock worth $1,021,000 after buying an additional 33,879 shares during the last quarter. Finally, Syon Capital LLC raised its holdings in Envista by 167.3% during the fourth quarter. Syon Capital LLC now owns 31,643 shares of the company's stock valued at $687,000 after buying an additional 19,807 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on NVST shares. Weiss Ratings restated a "sell (d)" rating on shares of Envista in a report on Monday, December 29th. Evercore ISI set a $32.00 price target on Envista and gave the company an "outperform" rating in a research report on Friday, February 6th. Stifel Nicolaus set a $31.00 price objective on Envista in a report on Friday, February 6th. William Blair raised shares of Envista from a "hold" rating to an "outperform" rating in a research note on Friday, February 6th. Finally, Morgan Stanley set a $19.00 target price on shares of Envista in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $27.43.
View Our Latest Stock Report on NVST
Envista News Roundup
Here are the key news stories impacting Envista this week:
- Positive Sentiment: Barclays raised its price target from $24 to $34 and moved NVST to an "overweight" rating, signaling stronger institutional conviction and giving the stock more upside momentum. Article Title
- Positive Sentiment: Short interest dropped ~23.3% in January to ~8.09M shares (about 5.0% of float, 3.1 days to cover), reducing one bearish force and removing a potential short-squeeze overhang. (Data reported 2/10/2026)
- Positive Sentiment: Zacks and other broker commentary have highlighted NVST as a buy/upgrade candidate amid sector rotation and AI-related market noise, reinforcing the positive analyst narrative around growth and execution. Article Title
- Positive Sentiment: Coverage highlighting Envista as a strong growth stock and noting that the name is gaining renewed focus as healthcare/NYSE composites strengthen, supporting continued investor interest. Article Title
- Neutral Sentiment: Mizuho raised its price target from $24 to $27 but kept a "neutral" rating — a modest improvement but still below the current market level, which may temper upside expectations for some investors. Article Title
- Negative Sentiment: Insider selling: SVP Mischa Reis sold 9,675 shares at about $30 (roughly $290K), reducing her stake by ~23%. Insider sales can create short-term nervousness about insider conviction even when not uncommon. SEC Filing
Envista Company Profile
(
Get Free Report)
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
